Lexeo Therapeutics, Inc./$LXEO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Lexeo Therapeutics, Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.
- Ticker
- $LXEO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 63
- Headquarters
- New York, United States
- Website
- www.lexeotx.com
LXEO Metrics
BasicAdvanced
$258M
-
-$1.15
1.47
-
Price and volume
Market cap
$258M
Beta
1.47
52-week high
$10.99
52-week low
$2.55
Average daily volume
1.8M
Financial strength
Current ratio
13.887
Quick ratio
13.574
Long term debt to equity
0.018
Total debt to equity
0.029
Interest coverage (TTM)
-1,302.97%
Profitability
EBITDA (TTM)
-94.504
Management effectiveness
Return on assets (TTM)
-27.59%
Return on equity (TTM)
-46.76%
Valuation
Price to book
1.05
Price to tangible book (TTM)
1.05
Price to free cash flow (TTM)
-2.696
Free cash flow yield (TTM)
-37.09%
Free cash flow per share (TTM)
-1.165
Growth
Earnings per share change (TTM)
-64.15%
3-year earnings per share growth (CAGR)
-69.17%
What the Analysts think about LXEO
Analyst ratings (Buy, Hold, Sell) for Lexeo Therapeutics, Inc. stock.
Analyst projections of the future price of Lexeo Therapeutics, Inc. stock.
LXEO Financial Performance
Revenues and expenses
LXEO Earnings Performance
Company profitability
Upcoming events
No upcoming events
LXEO News
AllArticlesVideos
Funds containing LXEO
Fund name | Fund size | $LXEO weighting |
|---|---|---|
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.01% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.01% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.01% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.01% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.